jueves, 19 de noviembre de 2026
Rethinking recruitment to clinical trials in Alzheimer's disease The Lancet Neurology (++...)
Rethinking recruitment to clinical trials in Alzheimer's disease
The Lancet Neurology
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00406-0/fulltext?dgcid=raven_jbs_etoc_email
Since the first regulatory approval of an anti-amyloid therapy in 2021, the number of clinical trials in Alzheimer's disease and of agents tested has continued to increase. According to the annual review of the Alzheimer's disease drug development pipeline, 158 agents were being tested in 192 phase 1–3 clinical trials in January 2026. The World Alzheimer Report 2026, A New Era in Dementia Clinical Trials, published by Alzheimer's Disease International in September, welcomes the vitality of this pipeline but warns that recruitment must improve for its promise to be fulfilled. The report is based on interviews with several dozen people living with dementia, their relatives, and clinical experts and aims to “demystify” clinical trials and to imrpove awareness of and trust in them.
https://www.thelancet.com/journals/laneur/issue/vol25no12/PIIS1474-4422(26)X2010-5
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario